Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia
2020 · Neuropsychopharmacology · 19 citations
https://doi.org/10.1038/s41386-020-00908-0